The use of constitutively active GPCRs in drug discovery and functional genomics

Nature Reviews Drug Discovery

Volumn 1, Issue 8, 2002, Pages 599-608

  Chalmers, Derek T ^a   Behan, Dominic P ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADRENOMEDULLIN; ALPHA ADRENERGIC RECEPTOR; ALPHA CHEMOKINE; ANAPHYLATOXIN; ANGIOTENSIN; BETA ADRENERGIC RECEPTOR; BETA CHEMOKINE; BOMBESIN; BRADYKININ; CHEMOKINE RECEPTOR; CHOLECYSTOKININ; CX3C CHEMOKINE; DOPAMINE; ENDOTHELIN; G PROTEIN COUPLED RECEPTOR; HISTAMINE; INTERLEUKIN 8; LIGAND; MELANOCORTIN; NEUROPEPTIDE Y; NEUROTENSIN; NEW DRUG; OCTOPAMINE; OPIATE; SEROTONIN; SOMATOSTATIN; TACHYKININ; UNINDEXED DRUG; UROTENSIN; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN;

DRUG DETERMINATION; DRUG RESEARCH; GENE SEQUENCE; GENOME ANALYSIS; GENOMICS; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; CHEMISTRY; CLASSIFICATION; GENETICS; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; GENOMICS; GTP-BINDING PROTEINS; HUMANS; RECEPTORS, CELL SURFACE; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036688175     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd872     Document Type: Review

References (61)

1. Marinissen, M. J. & Gutkind, J. S. G protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol. Sci. 22, 368-376 (2001).
2. Scussa, F. World's best-selling drugs. Med Ad News 21 No. 5, 1-46 (2002).
3. Marchese, A., George, S. R., Kolakowski, L. F., Lynch, K. R. & O'Dowd, B. F. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol. Sci. 20, 370-375 (1999).
4. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
5. Menzaghi, F., Behan, D. P. & Chalmers, D. T. Constitutively activated G protein-coupled receptors: a novel approach to CNS drug discovery. Curr. Drug Targets 1, 105-121 (2002).
6. Civelli, O. et al. Novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci. 24, 230-237 (2001).
7. Bunzow, J. R. et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 336, 783-787 (1998).
8. Meng, F. et al. Cloning and expression of the A2a adenosine receptor from guinea pig brain. Neurochem. Res. 19, 615-623 (1994).
9. Lovenberg, T. W. et al. Cloning and characterization of a functionally distinct corticotrophin-releasing factor receptor subtype from rat brain. Proc. Natl Acad. Sci. USA 92, 836-840 (1995).
10. Jakeda, S., Kadowaki, S., Haga, T, Takaesu, H. & Mitaku, S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 520, 97-101 (2002).
11. Karchin, R., Karplus, K. & Haussler, D. Classifying G-protein coupled receptors with support vector machines. Bioinformatics 18, 147-159 (2002).
12. Durant, G. J., Parsons, M. E. & Black, J. W. Potential histamine H2-receptor antagonists. 2. N-α-guanylhistamine. J. Med. Chem. 18, 830-833 (1975).
13. Wilson, S. et al. Orphan G-protein-coupled receptors: the next generation of drug targets? Br. J. Pharmacol. 125, 1387-1392 (1998).
14. Meunier, J. C. et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377, 532-535 (1995).
15. Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998).
16. Hinuma, S. et al. A prolactin-releasing peptide in the brain. Nature 393, 272-276 (1998).
17. Tatemoto, K. et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251, 471-476 (1998).
18. Kojima, M. et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656-660 (1999).
19. Erickson, J. R. et al. Edg-2Nzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid. J. Biol. Chem. 273, 1506-1510 (1998).
20. Heise, C. E. et al. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275, 30531-30536 (2000).
21. Chambers, J. et al. Melanin-concentrating hormone is the cognate ligand for the orphan G protein-coupled receptor SLC-1. Nature 400, 261-265 (1999).
22. Mori, M. et al. Urotensin II is the endogenous ligand of a G protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys. Res. Common. 265, 123-129 (1999).
23. Feighner, S. D. et al. Receptor for Motilin identified in the human gastrointestinal system. Science 284, 2184-2188 (1999).
24. Kojima, M. et al. Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). Biochem. Biophys. Res. Commun. 276, 435-438 (2000).
25. Elshourbagy, N. A. et al. Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor. J. Biol. Chem. 275, 25965-25971 (2000).
26. Lembo, P. M. C. et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. Nature Neurosci. 5, 201-209 (2002).
27. Masuda, Y. et al. Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem. Biophys. Res. Commun. 293, 396-402 (2002).
28. Costa, T. & Hertz, A. Antagonists with negative intrinsic activity at δ-opioid receptors coupled to GTP-binding proteins. Proc. Natl Acad. Sci. USA 86, 7321-7325 (1989).
29. Samama, P., Cotecchia, S., Costa, T. & Lefkowitz, R. J. A mutation-induced activated state of the β2-adrenergic receptor Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636 (1993 ).
30. Lefkowitz, R. J., Cotecchia, S., Samama, P. & Costa, T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307 (1993).
31. Parma, J. et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365, 649-651 (1993).
32. Parfitt, A. M. et al. Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH/PTH-related) receptor: comparison with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81, 3584-3588 (1996).
33. Balmforth, A. J., Lee, A. J., Warburton, P., Donnelly, D. & Ball, S. G. The conformational change responsible for the AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J. Biol. Chem. 272, 4245-4251 (1997).
34. Alewijnse, A. E. et al. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H (2) receptor. Mol. Pharmacol. 57, 890-898 (2000).
35. Huang, P. et al. Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry 40, 13501-13509 (2001).
36. 1B-adrenergic receptor is a key residue coupling TM helical movements to G-protein activation. Biochemistry 41, 588-596 (2002).
37. Behan, D. P. & Chalmers, D. T. The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr. Opin. Drug Discov. Dev. 4, 548-560 (2001).
38. Parnot, C. et al. Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc. Natl Acad. Sci. USA 97, 7615-7620 (2000).
39. Nakabayashi, K., Kudo, M., Kobilka, B. & Hsueh, A. J. W. Activation of lutenizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region. J. Biol. Chem. 275, 30264-30271 (2000).
40. Rasmussen, S. G. F. et al. Mutation of a highly conserved aspartic, acid in the β2 adrenergic receptor: constitutive activation, structural instability, and conformational rearrangement of transmembrane segment 6. Mol. Pharmacol. 56, 175-184 (1999).
41. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor Science 289, 739-745 (2000).
42. Lu, Z. L., Saldanha J. W. & Hulme, E. C. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23, 140-146 (2002).
43. Behan, D. P. & Chalmers, D. T. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease. WO Patent 9,846,995 (1997).
44. Lerner, M. R. Tools for investigating functional interactions between ligands and G protein-coupled receptors. Trends Neurosci. 17, 142-146 (1994).
45. Chen, G. et al. Use of constitutive G protein-coupled receptor activity for drug discovery. Mol. Pharmacol. 57, 125-134 (2000).
46. Strange, P. G. Mechanisms of inverse agonism at G protein-coupled receptors, Trends Pharmacol. Sci. 23, 89-95 (2002).
47. Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103-110 (2002).
48. Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15, 598-611 (2001).
49. Milligan, G., Bond, R. A. & Lee, M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol. Sci. 16, 10-13 (1995).
50. Smit, M. J. et al. Inverse agonism of histamine H2 antagonists accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl Acad. Sci. USA 93, 6802-6807 (1996).
51. Morisset, S. et al. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408, 860-864 (2000).
52. Carroll, F. Y. et al. BAY-36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 59, 965-973 (2000).
53. Fawzi, A. B. et al. SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors. Mol. Pharmacol. 59, 30-37 (2000).
54. Wada, M., Nagano, N. & Nemeth, E. F. The calcium receptor and calcimimetics. Curr. Opin. Nephrol. Hypertens. 8, 429-433 (1999).
55. Soudijn W., van Wijngaarden, I. & Izerman, A. P. Allosteric modulation of G-protein-coupled receptors. Exp. Opin. Therap. Patents 11, 1889-1904 (2001).
56. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
57. Krogh, A., Brown, M., Mian, I. S., Sjolander, K. & Haussler, D. Hidden Markov, models in computational biology: application to protein modeling. J. Mol. Biol. 235, 1501-1531 (1994).
58. Karplus, K., Barrett, C. & Hughey, R. Hidden Markov models for detecting remote protein homologies. Bioinformatics 14, 846-856 (1998).
59. Babinet, C. & Cohen-Tannoudji M. Genome engineering via homologous recombination in mouse embryonic stem (ES) cells: an amazingly versatile tool for the study of mammalian biology. An. Acad. Bras. Cienc. 73, 365-383 (2001).
60. Harris, S. & Foord, S. M. Transgenic gene knock-outs: functional genomics and therapeutic target selection. Pharmacogenomics 1, 433-443 (2000).
61. Sautel, M. & Milligan, G. Molecular manipulation of G-protein-coupled receptors: a new avenue into drug discovery. Curr. Med. Chem. 7, 889-896 (2000).